Publication date: Jul 02, 2025
Previous studies suggest that butyrylcholinesterase (BChE), an enzyme involved in the cholinergic anti-inflammatory pathway, may be linked to inflammation, disease severity, and risk of death in COVID-19 patients. Extending earlier work on BChE and COVID-19 severity, this study investigates additional factors such as age, sex, vaccination status, and symptom profiles. We analyzed 462 patients with polymerase chain reaction (PCR)-confirmed COVID-19 from the first epidemic wave in Spain, examining the association between BChE activity, clinical outcomes, demographic factors, and symptoms. The cohort consisted of 78 asymptomatic patients, 200 patients with mild symptoms, 122 patients with severe symptoms, and 62 critically ill patients. Of the patients in the severe symptoms group and critically ill patients, 26 died within 30 days of diagnosis. Our results showed that BChE activity was not affected by sex but decreased significantly with age (P
Open Access PDF
| Concepts | Keywords |
|---|---|
| Butyrylcholinesterase | Butyrylcholinesterase |
| Inflammatory | COVID-19 |
| Pcr | Ellman’s assay |
| Spain | Mortality |
| Vaccination | Severity |
| Symptoms |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | MESH | inflammation |
| disease | MESH | death |
| disease | IDO | symptom |
| disease | MESH | critically ill |
| disease | MESH | Long Covid |
| disease | IDO | assay |